0001104659-24-005888.txt : 20240123 0001104659-24-005888.hdr.sgml : 20240123 20240123161600 ACCESSION NUMBER: 0001104659-24-005888 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240116 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240123 DATE AS OF CHANGE: 20240123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NRX Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001719406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822844431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38302 FILM NUMBER: 24552843 BUSINESS ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: 484-254-6134 MAIL ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 FORMER COMPANY: FORMER CONFORMED NAME: Big Rock Partners Acquisition Corp. DATE OF NAME CHANGE: 20171012 8-K 1 tm243930d1_8k.htm FORM 8-K
false 0001719406 0001719406 2024-01-16 2024-01-16 0001719406 us-gaap:CommonStockMember 2024-01-16 2024-01-16 0001719406 us-gaap:WarrantMember 2024-01-16 2024-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) January 16, 2024

 

 NRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38302   82-2844431
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

1201 Orange Street, Suite 600

Wilmington, Delaware 

   19801
(Address of principal executive offices)   (Zip Code)

 

(484) 254-6134  

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.001 per share   NRXP   The Nasdaq Stock Market LLC
Warrants to purchase one share of Common Stock   NRXPW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel, which hearing was held on January 4, 2024.

 

On January 16, 2024, the Panel granted the Company’s request for an exception to the Nasdaq listing rules until April 16, 2024, to demonstrate compliance with the Rule. Such exception is subject to the following conditions:

 

1.The Company filing all necessary documentation required to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market on or before January 19, 2024; and

 

2.The Company demonstrating compliance with Listing Rule 5550(a)(2) on or before April 16, 2024.

 

We are diligently working to evidence compliance with the Rule; however, there can be no assurance that the Panel will determine to continue the Company’s listing or that the Company will be able to evidence compliance with the applicable listing criteria within the time period of any extension that may be granted by the Panel.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to: inability of the Company to achieve any of the potential developments identified above; the timing for achieving the potential developments identified above; there is no assurance as to how the potential developments will impact the Company's stock price; and other factors, including risks and uncertainties with respect to the Company, set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

 

Item 7.01. Regulation FD Disclosure.

 

On January 17, 2024, the Company issued a press release announcing the Panel’s decision. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
99.1   Press Release, dated January 17, 2024
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NRX PHARMACEUTICALS, INC.
   
Date: January 23, 2024 By: /s/ Stephen Willard
  Name: Stephen Willard
  Title: Acting General Counsel

 

 

 

 EX-99.1 2 tm243930d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination

 

RADNOR, Pa., January 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for suicidal depression, chronic pain, and PTSD, today announced that on January 16, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for the transfer of its listing to The Nasdaq Capital Market, subject to the Company evidencing compliance with all applicable criteria for continued listing on the Capital Market tier, including the $35 million in market value of listed securities (MVLS) and the $1.00 bid price requirements. The Company believes it has already satisfied the market value of listed securities requirement and is working to evidence compliance with the minimum bid price requirement by April 16, 2024, as required by the Panel’s decision. An issuer must evidence compliance with the minimum threshold for at least ten consecutive business days to be deemed by Nasdaq to have complied with the applicable requirement.

 

“NRx is pleased to share this encouraging news with our shareholders as we continue to meet our drug development milestones as set outlined in our recent communications (NRx Corporate Presentation). This quarter we aim to file our first New Drug Application for NRX-100 (ketamine) for treatment of acute suicidal depression and look forward to announcing top line results from our phase 2b/3 trial of NRX-101 (D-cycloserine/lurasidone) in the treatment of suicidal bipolar depression. These milestones, together with additional updates, are anticipated in advance of the Nasdaq compliance date,” said Stephen Willard, JD, CEO of NRx.

 

About NRx Pharmaceuticals

 

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

 

NRx has recently announced plans to submit a New Drug Application for ketamine in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

 

Cautionary Note Regarding Forward-Looking Statements

 

This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.

 

 

 

 

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

 

CORPORATE CONTACTS

 

Jeremy Feffer

LifeSci Advisors, Inc.

jfeffer@lifesciadvisors.com

 

Matthew Duffy

Chief Business Officer

mduffy@nrxpharma.com

 

 

 

 EX-101.SCH 3 nrxp-20240116.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 nrxp-20240116_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 nrxp-20240116_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 nrxp-20240116_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 16, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 16, 2024
Entity File Number 001-38302
Entity Registrant Name NRX PHARMACEUTICALS, INC.
Entity Central Index Key 0001719406
Entity Tax Identification Number 82-2844431
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1201 Orange Street
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Wilmington
Entity Address, State or Province DE
Entity Address, Postal Zip Code 19801
City Area Code 484
Local Phone Number 254-6134
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol NRXP
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants to purchase one share of Common Stock
Trading Symbol NRXPW
Security Exchange Name NASDAQ
XML 8 tm243930d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001719406 2024-01-16 2024-01-16 0001719406 us-gaap:CommonStockMember 2024-01-16 2024-01-16 0001719406 us-gaap:WarrantMember 2024-01-16 2024-01-16 iso4217:USD shares iso4217:USD shares false 0001719406 8-K 2024-01-16 NRX PHARMACEUTICALS, INC. DE 001-38302 82-2844431 1201 Orange Street Suite 600 Wilmington DE 19801 484 254-6134 false false false false Common Stock, par value $0.001 per share NRXP NASDAQ Warrants to purchase one share of Common Stock NRXPW NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /V!-U@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #]@3=8.FV&ULS9+! M3L,P#(9?!>7>NDD9AZCK96BG(2$Q"<0M2KPMHDFCQ*C=VY.6K1."!^ 8^\_G MSY(;':3N(S['/F DB^EN=)U/4HGW"'JO>"2K^2J?I]&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #]@3=8=.(@?NT$ ##%0 & 'AL+W=O,'TB M,Y["-PNI$F;@5"U=G2G.HB(HB5WJ>6TW82)U^MWBLXGJ=V5N8I'RB2(Z3Q*F M7B]Y+-<]QW?>/G@0RY6Q'[C];L:6?,K-EVRBX,PM52*1\%0+F1+%%SUGX%]< MMJ@-**[X7?"UWCDF]E;F4C[9DW'4&BO!X-\S'_(XMDK \?=6U"E_ MTP;N'K^I7Q_2N9)A#K@T9IYM*LQG[>@-7D;'AB?ZK#G$C&=1+ MVG*^T!D+><^!>M5'+<:$*R$C,DHC M58NRZX4EE73875 M+M':J. H-<*\DFL1LT-X'OA2:*,8K-D= M2VH7"M>Y>_B#3#X-'FX'P]&7V7@XN)D>D?'=\ 1A[)2,G4,8AY!1Q6)HR8B_ MD,_\M8X25_)@Z<[\\\!K(UCG)=;Y(5@S]D+&$;")A0@W1K$_L;ABAQ[33A $ M+1_!\[W*2KU# ,=I*%4F5<%V1*8&.H%(188RAP6%=951;<(;U*]&&.2.W_N' M0 ZB"$Q1'[T=D,)K[]-Z,ES2IYY/[J&8EQSN5L$HPDBKD>"C!HZ3SM:REA27 MG.8"Q0Q#/BED2E&5\T&'S?W]W1E M'4Z4?!9I6)]I7!.OP6I<^+C+OT>;2&W :/X4V?[FP!7]\XZ'-G$U+WS<[(LD M#F"#NQ\%%P@ZV-SRJT'AXPY_(T-8D\E*IMCD:A"AI\%QVV^A1-58\'$W?U3" M&)["PB1)GF[-5]=2X4)-^PZ_&@D^[N!3&8M0&&@;<@OEK02+:WEPE28>6HT MBIOT1/'C$):'0W]MMH>P0^.*W"\6]?EKT&LDJWR?XB;]'[*QUCF0-0+BLHV M.T\ !]G]*.%J:?/Y"RB8E2VVC*6U>X\&P4:TRN@I[LRVX&&;,34R?")?;[EM MQOHG$E3G@X\DM+)\&GR#IRC4\C_*7,T"BCOW3!C8FLL%\>F/\Y_(E(?X->0>?(1U\Y5-.EA4^#_]$K#4K;!&EB),ER!86C01CNO>@0 M^Q.[W83!5P.HA4^*YHYI$+ =\XBA5*.FU? 8<'#+- CM;QEWYY6'FQ,BL>$LWE\;(I#A<<0:CV5X WR^D-&\G]L5?^=ZV M_P]02P,$% @ _8$W6)^@&_"Q @ X@P T !X;"]S='EL97,N>&UL MW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75E MW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R M5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :# M7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T% M8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE M+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 M Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2S MP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DM MC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D M7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$ MKQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3 M\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ _8$W6)>*NQS $P( L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&H MP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[ MA$O\G7D(GP&LK\,S4 M-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0& M[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y: MYU;*O8=7LN48Y0]02P,$% @ _8$W6"0>FZ*M ^ $ !H !X M;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D M6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP M#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZT MYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( /V!-UAED'F2&0$ ,\# 3 M 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP M 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=. M8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9 MP&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I& M0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC", MS[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ M 0(4 Q0 ( /V!-UATXB!^[00 ,,5 8 " @0X( !X M;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " #]@3=899!YDAD! #/ P $P @ $[ L$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "%% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nrxp-20240116.xsd nrxp-20240116_def.xml nrxp-20240116_lab.xml nrxp-20240116_pre.xml tm243930d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm243930d1_8k.htm": { "nsprefix": "nrxp", "nsuri": "http://nrx.com/20240116", "dts": { "schema": { "local": [ "nrxp-20240116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "nrxp-20240116_def.xml" ] }, "labelLink": { "local": [ "nrxp-20240116_lab.xml" ] }, "presentationLink": { "local": [ "nrxp-20240116_pre.xml" ] }, "inline": { "local": [ "tm243930d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://nrx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm243930d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm243930d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://nrx.com/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-005888-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-005888-xbrl.zip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